Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Sci. STKE, 8 June 2004
Vol. 2004, Issue 236, p. tw210
[DOI: 10.1126/stke.2362004tw210]


CANCER Toward Tailored Cancer Therapy

Lung cancer is the leading cause of cancer deaths worldwide, and more effective therapies are urgently needed. The U.S. Food and Drug Administration recently approved the drug gefitinib (also known as Iressa), a small molecule that inhibits the tyrosine kinase activity of the epidermal growth factor (EGF) receptor, which is overexpressed in many lung tumors. In clinical trials, the majority of lung cancer patients do not respond to gefitinib, but a small percentage show dramatic tumor regression. Paez et al. (see the Perspective by Minna et al.) have found a possible molecular explanation for these clinical results: The tumors of patients who respond to gefitinib treatment are much more likely to have mutations in the EGF receptor gene than are nonresponders. This discovery may help clinicians identify which patients are most likely to benefit from gefitinib, thus bringing the concept of personalized cancer therapy a step closer to reality.

J. G. Paez, P. A. Jänne, J. C. Lee, S. Tracy, H. Greulich, S. Gabriel, P. Herman, F. J. Kaye, N. Lindeman, T. J. Boggon, K. Naoki, H. Sasaki, Y. Fujii, M. J. Eck, W. R. Sellers, B. E. Johnson, M. Meyerson, EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 304, 1497-1500 (2004). [Abstract] [Full Text]

J. D. Minna, A. F. Gazdar, S. R. Sprang, J. Herz, A bull's eye for targeted lung cancer therapy. Science 304, 1458-1461 (2004). [Abstract] [Full Text]

Citation: Toward Tailored Cancer Therapy. Sci. STKE 2004, tw210 (2004).

To Advertise     Find Products

Science Signaling. ISSN 1937-9145 (online), 1945-0877 (print). Pre-2008: Science's STKE. ISSN 1525-8882